Testing a new drug for advanced solid tumors or EGFR-mutant lung cancer
Part of Cancer clinical trials.
This trial tests a new drug called JH021 in people with advanced solid tumors or a specific type of lung cancer. The goal is to see if it can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer has continued to grow despite standard treatments, or you cannot take or refuse those treatments.
- You have a solid tumor (Part Ia) or a type of lung cancer with an EGFR mutation that has become resistant to newer EGFR inhibitor drugs and you have had chemotherapy (Part Ib).
- You have at least one tumor that can be measured on imaging tests.
- You are able to care for yourself and are not bedridden.
- Your blood counts, liver, kidney, and blood clotting tests are within certain ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
This trial tests a new drug, HS-20117, for people with advanced solid tumors, especially certain types of lung cancer. It aims to see if the drug is safe and effective when other treatments have stopped working.
This study tests a new drug called JY016 for people with advanced solid tumors that have a protein called EGFR on their surface. The drug aims to help the immune system attack the cancer cells. It may be an option if standard treatments have stopped working or aren't suitable.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.